NCT02388997View on ClinicalTrials.gov

Treatment With Omalizumab to Improve the Asthmatic Response to Rhinovirus Experimental Infection With Rhinovirus

PHASE2CompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

February 1, 2013

Primary Completion Date

May 4, 2017

Study Completion Date

May 4, 2017

Conditions
Asthma
Interventions
DRUG

omalizumab

This medication has been approved for clinical use to treat patients with moderate to severe asthma by the FDA in 2003 and for use in this study (BB-IND# 10510)

BIOLOGICAL

Rhinovirus (strain 16)

This strain of pooled rhinovirus has been approved for use in experimental challenges (BB-IND# 15162) and for use in this study (BB-IND# 10510) by the FDA.

Trial Locations (1)

22908

University of Virginia, Charlottesville

All Listed Sponsors
collaborator

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

lead

University of Virginia

OTHER

NCT02388997 - Treatment With Omalizumab to Improve the Asthmatic Response to Rhinovirus Experimental Infection With Rhinovirus | Biotech Hunter | Biotech Hunter